Clinical survival, immunohistochemical assessment in terms of the expression level of several tumor markers (i.e., CD31, c-MYC, EGFR, Ki-67, p53, and VEGF) and the percentage of tumor cells in apoptosis (significant if >7% measured by the TUNEL assay staining) were the parameters measured in the study. The gene discussed is PECAM1; the disease is neoplasm.